Get the Stockscreener App
62.60
3.13%
-2.02
Pre-market:
62.90
0.30
+0.48%
Dexcom Inc stock is traded at $62.60, with a volume of 4.35M.
It is down -3.13% in the last 24 hours and down -6.50% over the past month.
DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.
See More
Previous Close:
$64.62
Open:
$64.87
24h Volume:
4.35M
Relative Volume:
0.92
Market Cap:
$24.16B
Revenue:
$4.66B
Net Income/Loss:
$836.30M
P/E Ratio:
29.91
EPS:
2.093
Net Cash Flow:
$1.08B
1W Performance:
-0.56%
1M Performance:
-6.50%
6M Performance:
-10.25%
1Y Performance:
-5.31%
1-Day Range:
$62.41
$65.00
1-Week Range:
$60.82
$65.29
52-Week Range:
$54.11
$89.98
Dexcom Inc Stock (DXCM) Company Profile
Name
Dexcom Inc
Sector
Industry
Phone
(858) 200-0200
Address
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
62.60 | 24.16B | 4.66B | 836.30M | 1.08B | 2.093 |
ABT
Abbott Laboratories
|
92.72 | 161.12B | 45.13B | 6.28B | 7.40B | 3.5895 |
SYK
Stryker Corp
|
327.30 | 125.35B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
82.00 | 105.28B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
59.52 | 88.46B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
79.71 | 45.96B | 6.07B | 1.06B | 1.34B | 1.8063 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-24-26 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-12-26 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-02-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-25-25 | Initiated | Evercore ISI | In-line |
| Oct-21-25 | Resumed | Stifel | Buy |
| Sep-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-21-25 | Initiated | Argus | Buy |
| Jun-16-25 | Initiated | Truist | Buy |
| May-30-25 | Initiated | Goldman | Buy |
| Apr-10-25 | Initiated | Mizuho | Outperform |
| Feb-03-25 | Upgrade | Redburn Atlantic | Neutral → Buy |
| Jan-16-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jul-26-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-30-24 | Initiated | Redburn Atlantic | Neutral |
| Mar-12-24 | Initiated | RBC Capital Mkts | Outperform |
| May-30-23 | Resumed | Morgan Stanley | Equal-Weight |
| Apr-17-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Mar-29-23 | Initiated | UBS | Buy |
| Jan-26-23 | Initiated | Wolfe Research | Outperform |
| Oct-18-22 | Initiated | Barclays | Equal Weight |
| Oct-12-22 | Initiated | Jefferies | Buy |
| Jul-15-22 | Initiated | Bernstein | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-03-22 | Upgrade | BTIG Research | Neutral → Buy |
| Jan-19-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-07-22 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-18-21 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-21-21 | Resumed | Cowen | Outperform |
| May-28-21 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Overweight |
| Jan-06-21 | Upgrade | UBS | Neutral → Buy |
| Oct-02-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| May-27-20 | Reiterated | Piper Sandler | Overweight |
| May-14-20 | Initiated | Wells Fargo | Equal Weight |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Nov-07-19 | Reiterated | Canaccord Genuity | Buy |
| Nov-07-19 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-19 | Initiated | Stifel | Buy |
| Nov-28-18 | Initiated | UBS | Neutral |
| Oct-19-18 | Upgrade | Goldman | Sell → Neutral |
| Sep-12-18 | Upgrade | Northland Capital | Under Perform → Market Perform |
| Aug-02-18 | Reiterated | Canaccord Genuity | Buy |
| Jul-02-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jun-08-18 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-18 | Initiated | BofA/Merrill | Buy |
| May-03-18 | Reiterated | Canaccord Genuity | Buy |
| Apr-04-18 | Initiated | Goldman | Sell |
| Apr-04-18 | Initiated | Guggenheim | Neutral |
| Mar-23-18 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-04-18 | Downgrade | Northland Capital | Market Perform → Under Perform |
| Sep-28-17 | Reiterated | Wedbush | Outperform |
View All
Dexcom Inc Stock (DXCM) Latest News
A Look at DexCom Inc (DXCM) After 3.1% Decline -- GF Value $109. - GuruFocus
DexCom Inc. stock outperforms competitors despite losses on the day - MarketWatch
A Look At Dexcom (DXCM) Valuation As Shares Lag And Fair Value Estimates Point Higher - Yahoo Finance
DexCom Inc. stock outperforms competitors on strong trading day - MarketWatch
Better Medical Device Stock Right Now: Abbott Laboratories vs. Dexcom - The Motley Fool
Devon Energy Corp stock (US2521311074): Why Google Discover changes matter more now - AD HOC NEWS
DexCom, Inc. (DXCM) Stock Analysis: Strong Buy Ratings And A 35.78% Potential Upside - DirectorsTalk Interviews
BTIG Maintains DexCom (DXCM) Buy Recommendation - MSN
DexCom Projected to Grow Profits as Q1 2026 Earnings Date Approaches - HarianBasis.co
Dexcom Inc. stock (US2521311074): Is continuous glucose monitoring strong enough to unlock new upsid - AD HOC NEWS
DexCom’s Quarterly Earnings Preview: What You Need to Know - Yahoo Finance
Devon Energy Corp stock (US2521311074): Is its shale production edge strong enough to unlock new ups - AD HOC NEWS
Lobbying Update: $75,000 of DEXCOM lobbying was just disclosed - Quiver Quantitative
TWIN CITY PRIVATE WEALTH, LLC's DexCom Inc(DXCM) Holding History - GuruFocus
DexCom, Inc. $DXCM Shares Purchased by Moran Wealth Management LLC - MarketBeat
KBC Group NV Sells 133,500 Shares of DexCom, Inc. $DXCM - MarketBeat
Chicago Capital LLC Reduces Position in DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. $DXCM Shares Purchased by Assetmark Inc. - MarketBeat
TransMedics & Dexcom: Healthcare Stocks for Long-Term GrowthNews and Statistics - IndexBox
A Look at DexCom Inc (DXCM) After 4.5% Gain -- GF Value $109.11 vs Price $63.98 - GuruFocus
Dexcom EVP Brown sells $107k in shares By Investing.com - Investing.com South Africa
Dexcom EVP Brown sells $107k in shares - Investing.com
Dexcom (DXCM) EVP sells 1,700 shares, still holds 111,204 - Stock Titan
Here's Why You Should Add DexCom Stock to Your Portfolio Now - TradingView
DexCom, Inc. $DXCM Shares Sold by Robeco Institutional Asset Management B.V. - MarketBeat
3 Reasons Investors Love DexCom (DXCM) - Barchart
DEXCOM INC ($DXCM) President & CEO 2025 Pay Revealed - Quiver Quantitative
DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
DexCom | ARS: Annual Report to Security Holders - Moomoo
[ARS] DEXCOM INC SEC Filing - Stock Titan
Dexcom (NASDAQ: DXCM) posts growth, seeks votes on board, pay and auditor - Stock Titan
Michael Brown (DXCM) files Form 144 to sell 1,700 restricted shares - Stock Titan
DexCom (DXCM) Upgraded to Buy: Here's Why - Yahoo Finance
Sumitomo Mitsui Trust Group Inc. Sells 15,977 Shares of DexCom, Inc. $DXCM - MarketBeat
DexCom, Inc. $DXCM Shares Sold by Massachusetts Financial Services Co. MA - MarketBeat
Dexcom Inc. stock (US2521311074): Why does its continuous glucose monitoring edge matter more now? - AD HOC NEWS
Dexcom Inc. stock (US2521311074): Why does its CGM leadership matter more now for U.S. investors? - AD HOC NEWS
Here's Why DexCom (DXCM) is a Strong Growth Stock - Yahoo Finance
DexCom Inc. stock underperforms Monday when compared to competitors - MarketWatch
Q4 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks - Yahoo Finance
BTIG Research Adjusts DexCom Price Target to $80 From $85, Maintains Buy Rating - marketscreener.com
DexCom Salaries - Comparably
DexCom, Inc. (DXCM) Stock Analysis: Investors Eye A 36% Upside Potential - DirectorsTalk Interviews
Greenup Street Wealth Management Invests in DexCom - National Today
Greenup Street Wealth Management LLC Makes New Investment in DexCom, Inc. $DXCM - MarketBeat
Risk Analysis: Can DexCom Inc be the next market leader2026 Snapshot & Weekly High Return Opportunities - baoquankhu1.vn
Trend Recap: Can DexCom Inc be the next market leaderPortfolio Profit Report & High Accuracy Trade Alerts - baoquankhu1.vn
Wells Fargo Maintains DexCom (DXCM) Overweight Recommendation - MSN
DexCom (XSWX:DXCM) Other Assets for Banks - GuruFocus
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
Dexcom Inc. stock (US2521311074): Is continuous glucose monitoring strong enough to drive U.S. inves - AD HOC NEWS
Dexcom Inc Stock (DXCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):